{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:10:13Z","timestamp":1789985413685,"version":"4.0.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.clim.2015.06.005","type":"journal-article","created":{"date-parts":[[2015,6,20]],"date-time":"2015-06-20T04:17:44Z","timestamp":1434773864000},"page":"277-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":172,"title":["Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis"],"prefix":"10.1016","volume":"160","author":[{"given":"Masaki","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Nakagishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Mizuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giyo","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Saikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syuji","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Yachie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2015.06.005_bb0005","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/gene.2012.3","article-title":"Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment","volume":"13","author":"Ravelli","year":"2012","journal-title":"Genes Immun."},{"key":"10.1016\/j.clim.2015.06.005_bb0010","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/nrrheum.2011.68","article-title":"Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions","volume":"7","author":"Mellins","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.clim.2015.06.005_bb0015","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens","year":"2007","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2015.06.005_bb0020","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/art.22416","article-title":"The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis","volume":"56","author":"Bleesing","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2015.06.005_bb0025","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/adc.85.5.421","article-title":"Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders","volume":"85","author":"Sawhney","year":"2001","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.clim.2015.06.005_bb0030","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/rheumatology\/40.11.1285","article-title":"Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients","volume":"40","author":"St\u00e9phan","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2015.06.005_bb0035","first-page":"401","article-title":"Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis","volume":"30","author":"Ramanan","year":"2003","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2015.06.005_bb0040","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00002281-200209000-00012","article-title":"Macrophage activation syndrome","volume":"14","author":"Ravelli","year":"2002","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.clim.2015.06.005_bb0045","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/01.bor.0000381996.69261.71","article-title":"Macrophage activation syndrome: advances towards understanding pathogenesis","volume":"22","author":"Grom","year":"2010","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.clim.2015.06.005_bb0050","first-page":"121","article-title":"Is macrophage activation syndrome a new entity?","volume":"20","author":"Athreya","year":"2002","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.clim.2015.06.005_bb0055","first-page":"2513","article-title":"Macrophage activation syndrome\u2014what\u2019s in a name!","volume":"30","author":"Ramanan","year":"2003","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2015.06.005_bb0060","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/rheumatology\/kem271","article-title":"New insights in systemic juvenile idiopathic arthritis\u2014from pathophysiology to treatment","volume":"47","author":"Frosch","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2015.06.005_bb0065","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/ard.2006.061853","article-title":"Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study","volume":"66","author":"de Jager","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2015.06.005_bb0070","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clim.2015.04.018","article-title":"Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches","volume":"159","author":"Bruck","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2015.06.005_bb0075","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","article-title":"Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis","volume":"49","author":"Shimizu","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2015.06.005_bb0080","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keu524","article-title":"Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon \u03b3","author":"Put","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2015.06.005_bb0085","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1546-0096-9-15","article-title":"Monitoring serum IL-18 levels is useful for treatment of a patient with systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome","volume":"9","author":"Shigemura","year":"2011","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"10.1016\/j.clim.2015.06.005_bb0090","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.cyto.2012.11.025","article-title":"Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles","volume":"61","author":"Shimizu","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.clim.2015.06.005_bb0095","first-page":"390","article-title":"International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton","volume":"31","author":"Petty","year":"2001","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2015.06.005_bb0100","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jpeds.2004.12.016","article-title":"Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"46","author":"Ravelli","year":"2005","journal-title":"J. Pediatr."},{"key":"10.1016\/j.clim.2015.06.005_bb0105","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.clim.2009.09.010","article-title":"Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states","volume":"134","author":"Macaubas","year":"2010","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2015.06.005_bb0110","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clim.2011.12.008","article-title":"Alternative activation in systemic juvenile idiopathic arthritis monocytes","volume":"142","author":"Macaubas","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2015.06.005_bb0115","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cyto.2012.05.003","article-title":"Compensated inflammation in systemic juvenile idiopathic arthritis: role of alternatively activated macrophages","volume":"60","author":"Shimizu","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.clim.2015.06.005_bb0120","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2741\/2692","article-title":"Macrophage activation and polarization","volume":"13","author":"Martinez","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.clim.2015.06.005_bb0125","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2015.06.005_bb0130","first-page":"2071","article-title":"Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis","volume":"31","author":"Verbsky","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2015.06.005_bb0135","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2015.06.005_bb0140","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","article-title":"The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2015.06.005_bb0145","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cyto.2012.02.006","article-title":"Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6","volume":"58","author":"Shimizu","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.clim.2015.06.005_bb0150","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/art.21061","article-title":"Rapid responses to anakinra in patients with refractory adult-onset Still\u2019s disease","volume":"52","author":"Fitzgerald","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2015.06.005_bb0155","first-page":"1794","article-title":"Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still\u2019s disease","volume":"52","author":"Kawashima","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2015.06.005_bb0160","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/1529-0131(200107)44:7<1716::AID-ART298>3.0.CO;2-I","article-title":"Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still\u2019s disease","volume":"44","author":"Kawaguchi","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2015.06.005_bb0165","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/ard.49.5.283","article-title":"Comparison of long term evolution of adult onset and juvenile onset Still\u2019s disease, both followed up for more than 10years","volume":"49","author":"Cabane","year":"1990","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2015.06.005_bb0170","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/acr.22194","article-title":"Clinical manifestations of adult-onset Still\u2019s disease presenting with erosive arthritis: association with low levels of ferritin and interleukin-18","volume":"66","author":"Ichida","year":"2014","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2015.06.005_bb0175","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1128\/IAI.63.10.3966-3972.1995","article-title":"A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock","volume":"63","author":"Okamura","year":"1995","journal-title":"Infect. Immun."},{"key":"10.1016\/j.clim.2015.06.005_bb0180","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/378088a0","article-title":"Cloning of a new cytokine that induces IFN-g production by T cells","volume":"378","author":"Okamura","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.clim.2015.06.005_bb0185","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1189\/jlb.0602313","article-title":"Interleukin-18","volume":"73","author":"Gracie","year":"2003","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.clim.2015.06.005_bb0190","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2249.2004.02475.x","article-title":"Interleukin-18 as a potential target in inflammatory arthritis","volume":"136","author":"Gracie","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2015.06.005_bb0195","doi-asserted-by":"crossref","first-page":"13962","DOI":"10.1073\/pnas.96.24.13962","article-title":"IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils","volume":"96","author":"Yoshimoto","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2015.06.005_bb0200","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1002\/art.10389","article-title":"Highly elevated serum concentrations of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al","volume":"46","author":"Maeno","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2015.06.005_bb0205","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1074-7613(00)80596-8","article-title":"Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function","volume":"9","author":"Adachi","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2015.06.005_bb0210","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0952-7915(98)80163-5","article-title":"Regulation of interferon-gamma production by IL-12 and IL-18","volume":"10","author":"Okamura","year":"1998","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.clim.2015.06.005_bb0215","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar1453","article-title":"Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome","volume":"7","author":"Villanueva","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.clim.2015.06.005_bb0220","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1067\/mpd.2003.110","article-title":"Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome","volume":"142","author":"Grom","year":"2003","journal-title":"J. Pediatr."},{"key":"10.1016\/j.clim.2015.06.005_bb0225","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/art.20198","article-title":"Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?","volume":"50","author":"Grom","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2015.06.005_bb0230","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1002\/art.24750","article-title":"Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis","volume":"60","author":"de Jager","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2015.06.005_bb0235","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2249.2004.02475.x","article-title":"Interleukin-18 as a potential target in inflammatory arthritis","volume":"136","author":"Gracie","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2015.06.005_bb0240","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.clim.2012.03.004","article-title":"Transient impairment of NK cell function in an infant born to a mother with adult-onset Still\u2019s disease: perinatal effect of maternal IL-18","volume":"143","author":"Shimizu","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2015.06.005_bb0245","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/art.33496","article-title":"Amplification of the response to toll-like receptor ligands by prolonged exposure to interleukin-6 in mice","volume":"64","author":"Strippoli","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2015.06.005_bb0250","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3899\/jrheum.130690","article-title":"Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan","volume":"41","author":"Yokota","year":"2014","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2015.06.005_bb0255","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1002\/art.38472","article-title":"A56: macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab","volume":"66","author":"Ravelli","year":"2014","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2015.06.005_bb0260","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/ng.3089","article-title":"An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome","volume":"46","author":"Canna","year":"2014","journal-title":"Nat. Genet."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661615002077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661615002077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T22:36:07Z","timestamp":1599172567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661615002077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1521661615002077"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2015.06.005","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2015.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}